Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services. By submitting this information, I agree to the privacy policy and to learn more about ...

MA's rising earnings outlook and global momentum fuel optimism, but premium valuation and mounting regulatory risks temper ...

Circ-EGFR was identified as a novel predictive biomarker for cetuximab efficacy in KRAS wild-type metastatic colorectal ...

Good morning, and thank you for joining us today to discuss our third quarter 2025 financial results. Please note that we provided presentation slides on the Investor Relations section of our website.

The deceleration in CKD prevalence growth after 2012, along with the declining incidence trends may reflect the impact of the ...